Profile data is unavailable for this security.
About the company
Argenica Therapeutics Limited is an Australia-based clinical drug development company. The Company is focused on developing therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).
- Revenue in AUD (TTM)192.09k
- Net income in AUD-5.48m
- Incorporated2019
- Employees--
- LocationArgenica Therapeutics Ltd4/117 BroadwayNEDLANDS 6009AustraliaAUS
- Phone+61 89329-3396
- Websitehttps://argenica.com.au/